Korean Idiopathic Pulmonary Fibrosis Registry
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jong Sun Park, MD
- Email: jspark.im@gmail.com
Study Locations
-
-
-
Seongnam-si, Korea, Republic of, 13620
- Recruiting
- Seoul National University Bundang Hospital
-
Principal Investigator:
- Jong Sun Park, MD
-
Contact:
- Jong Sun Park, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- IPF patients diagnosed by multidisciplinary discussion
Exclusion Criteria:
- Other interstitial lung diseases except for IPF
- connective tissue disease-related ILD
- exposure-related ILD
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
survival of IPF
Time Frame: through study completion, an average of 1 year
|
lung function change (FVC, DLCO)
|
through study completion, an average of 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
survival
Time Frame: through study completion, an average of 1 year
|
death rate
|
through study completion, an average of 1 year
|
|
acute exacerbation
Time Frame: through study completion, an average of 1 year
|
rate of acute exacerbation
|
through study completion, an average of 1 year
|
|
incidence of comorbidity
Time Frame: through study completion, an average of 1 year
|
incidence of lung cancer
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Man Pyo Chung, MD, Samsung Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1.1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.